IPOs vs the virus

Some internet wandering led me to stumble on the following chart from PWC that left me a little dumbfounded, and prompted a stroll through some IPO facts and figures.

Who in their right minds would try to get their business listed on a stock exchange in the middle of a pandemic, and potentially in the teeth of a terrible recession? It turns out that 477 businesses did just that in Q3 this year, raising $116bn in the process.

According to EY “Q3 2020 was the most active third quarter in last 20 years by proceeds and the second highest third quarter by deal numbers”.

So where is this extravaganza of new listings? 23 of them turned up in London (details here at the LSE). The fun was mostly being had in the US. They were flying off the shelves at such a rate that the numbers are increasing by the day it seems. As of 24th November, 2020, according to stockanalysis.com: "There have been 401 IPOs on the US stock market this year, as of November 24, 2020. That is +81.4% more than the same time in 2019, which had 221 IPOs by this date."

Is there a spooky correlation between the number of people dying from respiratory illness and the volume of IPOs during the year? One for Tyler Vigen maybe...

Looking at that busy US IPO activity for 2019, (as at November 2020) 59% of the IPOs are higher than their initial listing price, 40% are lower. The top 10 are below:

IPO Date	Name	IPO Price	Current	Return
Apr 18, 2019	Zoom Video Communications	$36.00	$430.28	1095%
Jun 13, 2019	Fiverr International	$21.00	$200.00	852%
Oct 10, 2019	BioNTech SE	$15.00	$106.50	610%
Nov 21, 2019	SiTime	$13.00	$85.20	555%
Jun 28, 2019	Karuna Therapeutics	$16.00	$100.00	525%
Jun 6, 2019	GSX Techedu	$10.50	$63.90	509%
Mar 7, 2019	ShockWave Medical	$17.00	$98.64	480%
Apr 17, 2019	Turning Point Therapeutics	$18.00	$104.37	480%
May 2, 2019	Beyond Meat	$25.00	$140.96	464%
Dec 5, 2019	LMP Automotive Holdings	$5.00	$27.71	454%

The bottom 10 from 2019:

IPO Date	Name	IPO Price	Current	Return
Nov 8, 2019	ECMOHO Limited	$10.00	$1.43	-86%
Aug 15, 2019	9F Inc.	$9.50	$1.29	-86%
Feb 12, 2019	Anchiano Therapeutics	$11.50	$1.41	-88%
Nov 13, 2019	YayYo	$4.00	$0.4500	-89%
Feb 15, 2019	Stealth BioTherapeutics	$12.00	$1.30	-89%
Jul 31, 2019	Borr Drilling	$9.30	$0.800	-91%
Jan 4, 2019	China SXT Pharmaceuticals	$4.00	$0.290	-93%
Apr 5, 2019	Guardion Health Sciences	$4.00	$0.247	-94%
May 10, 2019	Sonim Technologies	$11.00	$0.585	-95%
Aug 1, 2019	Sundial Growers	$13.00	$0.241	-98%

2020 has been just as exciting. 61% of the new listing from this year are in the green, whilst 36% have lost money.

2020 top 10 IPOs:

IPO Date	Name	IPO Price	Current	Return
Aug 14, 2020	CureVac	$16.00	$85.06	432%
Aug 27, 2020	XPeng	$15.00	$72.17	381%
Apr 8, 2020	Keros Therapeutics	$16.00	$76.21	376%
Jul 17, 2020	ALX Oncology Holdings	$19.00	$82.28	333%
Feb 6, 2020	Schrodinger	$17.00	$67.65	298%
Jul 30, 2020	Li Auto	$11.50	$43.64	279%
Jul 17, 2020	Berkeley Lights	$22.00	$83.36	279%
May 22, 2020	Inari Medical	$19.00	$68.00	258%
Jun 5, 2020	Dada Nexus	$16.00	$52.03	225%
Aug 13, 2020	KE Holdings	$20.00	$62.97	215%

And the bottom 10:

IPO Date	Name	IPO Price	Current	Return
Feb 6, 2020	Casper Sleep	$12.00	$6.04	-50%
Jan 17, 2020	Velocity Financial	$13.00	$6.25	-52%
Sep 30, 2020	Boqii Holding	$10.00	$4.78	-52%
Feb 13, 2020	Muscle Maker	$5.00	$2.30	-54%
Feb 24, 2020	Zhongchao	$4.00	$1.82	-55%
Jan 30, 2020	AnPac Bio-Medical Science	$12.00	$3.49	-71%
Jan 17, 2020	Phoenix Tree Holdings	$13.50	$3.76	-72%
Jun 19, 2020	Progenity	$15.00	$3.64	-76%
Jan 17, 2020	Lizhi Inc.	$11.00	$2.48	-77%
Jun 30, 2020	Aditx Therapeutics	$9.00	$1.91	-79%

Exciting stuff, a bit racy for me.

The requirements for a new listing vary slightly from one exchange to another, as do the regulatory requirements. The LSE have a nice write up here and nicely summarised below. 

It all sounds like a nice wheeze to get some cash, perhaps the founders have the chance to offload some of their own investment tied up in the company. But a more sobering element is the cost. PWC again have a nice tool to allow a view of the potential costs.

As an example, a tech firm with revenues less than $100m wanting to list at a valuation in the range of $100m to $250m would end up having to hand over between $8m to $24m according to PWC. 

Some of these IPOs are SPACs - Special Purpose Acquisition Companies. There is a detailed and comprehensive write up from Harvard if these excite you. SPACs are companies with no commercial operations that are designed and built just to raise capital via an IPO. It then buys an existing business. They are known as "blank cheque" companies and have been around for decades, but the recent boom in IPOs have brought these to the public attention through some high profile listings.

I think IPOs are not for me, although one or two of the US businesses do look interesting. I prefer my investments to be a little less volatile.

October 2020 portfolio update

A wobbly set of markets in October. Not quite collapsing, but looking like they were considering it. Most markets drifted from green to red over the course of the month. In addition to the virus, in the UK Brexit headlines had Sterling whizzing around which tends to impact the overseas earners on the FTSE. 

Virus news continued to deteriorate across Europe and the US, with the predictions for a tough winter playing out. As health systems started to get stretched more restrictive social distancing measures were deployed. I get the impression many people are now suffering some fatigue from this, and can't wait to get out, even the morning commute is starting to look appealing to me.

The two elderly US gents vying to run their country managed to continue to squabble over social media, and just about managed a civilised second debate. The Trump team have publicly announced that they have given up trying to control the virus. Perhaps of no surprise is that the blue and red teams couldn’t agree on any more economic support for the country until the election is out of the way. Can a country of 330m people really not do better than these two? Ah well it will be over soon…maybe.

The portfolio stumbled this month, along with the wider markets. October brings to an end a nice run of monthly increases over the last 7 months, which equalled it's previous best run.

Portfolio performance
The portfolio was down -3.3% in October, ahead of my chosen benchmark (Vanguard FTSE All Share Accumulation) which was down -3.8% over the same period.

Best performers this month:
Dignity +23%

Abcam +20%

SAGA +10%

Worst performers this month:
Qinetiq -15%

Sage Group -12%

RELX -12%

October share purchase 1: RWS

RWS provide a range of highly technical translation services. Their business is divided into 4 segments:

• IP Services: patent translations/ filing/ research
• Life Sciences: language solutions for clinical trials and other aspects of technical support
• Moravia: localisation of products and content for international businesses
• Language Solutions: translation and interpretation services

They were listed in 2003, and have continually grown and developed their business both organically and through acquisitions. Earlier in the year RWS announced a merger with fellow translation firm SDL which specialises in AI based translation services. It follows acquisitions of various technology based firms over previous years, and now puts RWS as the market leader in the field. Following Terry Smith’s advice I decided to invest in RWS not because they might be the next big winner, but because they have already won.

RWS started life as translation firm Randall Woolcott Services. The Chairman, Andrew Brode bought the company along with 3i in 1995 and currently owns over 30% of the shares. He seems to have been doing something right as over the past 10 years, net margins and return on capital have both averaged in the mid-teens. Dividends have increased each year, at a compound rate of over 10%, and is currently covered more than 2.5x cash flow.

Their competitive advantage comes through providing highly technical and niche expertise, which increases client dependence on RWS. The acquisition of SDL cements their market leading position and increases scope for dominant pricing power. I prefer defensive companies, and suspect that RWS falls into this categorisation. Although clients will likely reduce discretionary spend during economic downturns, the critical and highly technical nature of RWS services should make for dependable income irrespective of macro-economic issues.

I see the main risks to RWS being the development of AI to provide such sophisticated translation and localisation services that the likes of RWS become superfluous. This is why RWS have been making their recent acquisitions, to ensure that they are part of the development of this AI. Over time we shall see how things pan out.

October share purchase 2: IHR

The second purchase this month was a small investment in Impact Healthcare REIT, this business owns real estate that is leased to care home providers. The trust has over 100 properties that are used by 11 different care home operators, with the rental income being split 3 ways - 60% from local authorities, 30% from private firms and 10% from the NHS.

Despite the COVID-19 disruptions the trust has collected all of it's rental income for the year to date, and has continued to pay dividends. Loan to value stands at 18%, and the weighted average lease is getting on for 20 years. The trust has been quietly improving on it's portfolio over the year, which is a trait I'm looking for at the moment - businesses that continue to operate relatively normally, not crippled by the pandemic.

The share price is down around 10% since the start of the year and I might well add to this holding if it stays that way. The risks of doing so would include changes to government policy over care home funding, and the care home providers needing to protect their occupants from the virus until we have better medical treatments available.

All weather portfolio

The All Weather Portfolio was the brainchild of Ray Dalio and his pals at Bridgewater which was eventually put to use in the 1990's. The history behind their thinking can be found here. As the name suggests the idea behind the portfolio construction was to build a fund that could generate returns in any economic environment. And looking at some basic stats it has done just that, and has a CAGR of around 7% since 2007.

The foundation of the portfolio was the notion that there are a limited number of factors driving returns in various asset classes. This was boiled down to 4 economic environments, a growing or shrinking economy, and rising or falling inflation as shown below:

And the idea that various asset classes outperformed in those different growth and/ or inflation environments:

However it wasn't simply a judgement of where to find the best returns, the All Weather portfolio was a risk parity portfolio. To this end the construction of the portfolio was designed such that each asset class was limited to the same amount of risk. Using the 4 environments above the portfolio was built such that there was an equal risk distributed across the different environments and the returns that each asset class would provide.

Risk, as I discussed in a previous post is a slippery notion in investing. But within the context of the All Weather portfolio, risk is viewed as volatility, and the portfolio is designed to reduce this whilst maintaining a steady return.

The exact contents of the Bridgewater portfolio is understandably kept under wraps. However, in an interview with self-help guru Tony Robbins, Dalio revealed the outline of the fund. It is roughly:

• 40% long-term bonds
• 30% stocks
• 15% intermediate-term bonds
• 7.5% gold
• 7.5% commodities

So armed with this information, using readily available investments one could recreate an approximation of the Bridgewater All Weather portfolio. And using the excellent portfoliovizualiser site, as noted above, we can see that using the above allocations, the portfolio seems to have performed pretty well, generating a reasonable 7% CAGR with a relatively low degree of volatility.

I decided to play around in googlesheets to try out a version of the portfolio with a few funds that seemed to cover off the main asset classes:

• 40% long-term bonds: SPDR Barclays 15+ Year Gilt UCITS ETF (GLTL)
• 30% stocks: S&P 500 UCITS ETF (VUSA)
• 15% intermediate-term bonds: Lyxor iBoxx $ Treasuries 1-3yr UCITS ETF (U13G)
• 7.5% gold: WisdomTree Physical Gold (PHGP)
• 7.5% commodities: Lyxor Commodities Thomson Reuters/CoreCommodity CRB (CRBU)

Feel free to download a copy of the spreadsheet and play around with the funds. I've not spent a lot of time trying to pick the best or cheapest funds so there may well be better alternatives out there.

One of the attractions of the portfolio is that it removes the need for market timing, whenever you start should make no difference. So I took data from around a year ago, as this would include the bull run in equities at the end of 2019, and the impact of the pandemic during 2020 (September 2019 - October 2020). During this period we can see that the different investment funds had a relatively limited range of diversion up until the pandemic hit the headlines, at which point, their reactions diverged considerably.

The overall performance of the portfolio assuming the above construction is below:

It held up pretty well, doing what it was designed to do I guess.

This type of investment does interest me, the last month at work has been crazy busy, (with this post stuck in draft for the past couple of weeks😴) and the idea of having a basket of investments that doesn't need much TLC other than an occasional rebalance certainly appeals. I enjoy the analysis and investigation of individual companies, and so far my own investments are doing ok. But should life get in the way of the investing process, I'd be quite happy to switch over to this sort of investing instead.

September 2020 portfolio update

September in the markets felt like a bit of a tease, a mix of selling and a threat of a significant fall, on other days there was a jump higher. A number of the big US tech firms saw their shares getting sold off, perhaps unsurprisingly given the journey they've been on since March. It was a bit more sedate in Blighty, the FTSE drifting gently lower.

Virus news worsened over the month with increased spread across the country, and with it came the risk of more restrictive social distancing. The US election got up to full steam, with Biden and Trump on a live "debate" - looked to me like two daft old men bickering. And in case that wasn't entertaining enough Brexit is back with a vengeance. Come to think of it, I'm surprised the markets haven't completely collapsed under all that nonsense.

No new additions to the portfolio this month, although an old-timer was topped up. And there is now one less holding, after waving goodbye to Network International.

Portfolio performance
The portfolio was up +2.1% in September, ahead of my chosen benchmark (Vanguard FTSE All Share Accumulation) which was down -1.7% over the same period.

Best performers this month:
888 Holdings +27%

Somero Enterprises +24%

Fulcrum Utilities +20%

Worst performers this month:
Dignity -21%

Craneware -10%

Eleco -10%

September share sale: NETW

Network International is a provider of payment services, focussed mainly on the Middle East. I bought into this in August 2019, after it's IPO in April 2019. This proved to be counter to my usual purchase targets, which are typically businesses that have been publicly listed for a while, and have demonstrated some degree of resilience over the past few years.

The main box ticking that NETW provided was that under "normal" circumstances - i.e. when we're not in the middle of a global pandemic - payment providers should be a pretty defensive business. People will buy stuff, no matter what. Exactly what they buy will change, but there will be a sustained requirement for a mechanism to pay. What it didn't have was a history as a publicly traded business, this deviation from my usual practice left me feeling a little uncomfortable when COVID-19 hit as I didn't have my usual research and business history to fall back on.

What really took the biscuit, however, was the share price getting cut in half on no news. Directors then made comforting statements, and bought some shares, pushing the price back up as dramatically as it fell. But I can't help wondering.... It reminded me of NMC, Finablr and Wirecard. Rather than wait this one out, I decided to sell at a 40% loss. I'd rather have that money invested in something else that I feel more comfortable with. Thankfully my approach to riskier investments meant I'd kept the amount invested small.

September share purchase: GSK

I've held shares in GlaxoSmithKline (GSK) for a while, I quite like buying shares in companies whose products are found in my house, toothpastes or painkillers, for example. They also have a range of pharmaceutical products, and vaccines. They've been in the news a fair bit recently, as has every other pharma business, trying to develop vaccines for COVID-19.

I'm less concerned about whether they cross the finish line in the race for the first COVID-19 vaccine, I'm invested because I suspect there will be a relatively stable demand for GSK products. As a pharma business, it has to run just to stand still, as there is a constant patent cliff edge over which it's products fall. Once they do, generic medicines can be spun up at much lower prices, and assuming they do the job, why pay for the more expensive brands. It also has a consumer healthcare arm which is a much less demanding part of the business.

GSK has merged it's healthcare business with that of Pfizer, which could be spun out as a separate company. It provides a tempting investment as it now comprises a huge over the counter healthcare business, that is likely to be more profitable and easier to manage than a pharmaceutical company. No specific news has been issued on this recently, but I'm content to wait and enjoy the ride.

Glaxo has a decent dividend at around 5%, and has been rebuilding it's dividend cover whilst holding the payment flat over the past few years. As of last year it was covered around 1.7x by free cash flow. The vaccines business has taken a bit of a hit this year, with fewer vaccinations due to healthcare systems being overwhelmed by COVID-19, but hopefully this will have recovered somewhat during the back end of the year.